Twex Exchange

PaNcryos

TWEX   > PaNcryos

PaNcryos

PaNcryos – €5m share offering.

PaNcryos is a pre-clinical stage biotech company, dedicated to improving life quality for millions of people suffering from Type 1 diabetes (T1D), by developing a best-in-class stem cell derived beta cell therapy, called PanInsula(TM).


T1D is a chronic autoimmune disease that affects millions of people worldwide and requires lifelong insulin injections to manage blood glucose levels. Despite advances in insulin delivery and monitoring devices, many patients still face serious complications such as kidney failure, blindness, nerve damage and cardiovascular disease.


There is an urgent need for a safe, effective, and scalable cell replacement therapy that can restore natural insulin production and improve quality of life for people with T1D. The global prevalence and incidence of T1D is set to increase due to changes in lifestyle and environmental factors. The overall level of unmet need in the T1D treatment space, coupled with the rising prevalence of T1D, present a big opportunity for drug developers to fulfill the remaining gaps in treatment.

PaNcryos Offering

Key Market Data